Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Dr.
Sledge: I personally don’t see any huge difference yet between
the three aromatase inhibitors. We, of course, don’t have any head-to-head
trials that tell us that one is superior to the other. So, I think for
the average clinician there is no database that would mandate using one
over the other. Now, that may change. One of the interesting things that
I think we’ve seen has been that at least one of the aromatase inhibitors,
exemestane, appears to work in some patients who have failed letrozole,
or Arimidex, or aminoglutethimide. We don’t have any data, interestingly
enough, about going in the opposite direction, though I’m sure we’ll
have that data probably in the next year or two. Why you should progress
on one aromatase inhibitor and respond to another is a biologic question
that I think is very interesting and one for which I certainly haven’t
heard a good explanation, as of yet.
Dr.
Love: What are you, yourself using in your practice?
Dr.
Sledge: Well I ‘d say, I probably have used Arimidex the most. Having
learned a dose of 1mg, once daily, it’s hard to come up with anything
simpler than that.
Formestane
is feasible and effective in elderly breast cancer patients with comorbidity
and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.; Rosso,
R., and Repetto, L. (Reprint available from: Venturino A PO S Lazzaro,
Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer Research & Treatment.
62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals of Surgical
Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803, 2000
Apr. No abstract
